

A photograph of a man with curly hair and a beard, wearing a blue and white plaid shirt, leaning over a young girl. The girl is wearing a white long-sleeved shirt with a grey wolf print and a straw hat with a pink band. They are in a lush green forest, looking at something on the ground. The background is filled with green foliage and trees.


Preparing for the COVID-19 Transition Phase Towards a 'new normal'



Ministerial Meeting COVID-19

17 April 2020


Approach to manage the Transition



Transition must be guided by public health principles, economic and societal considerations

Criteria to manage a controlled transition


1. Evidence COVID-19 transmission is controlled
2. Sufficient public health and health system capacities
3. Outbreak risks in high-vulnerability settings are minimized
4. Workplace preventive measures are established
5. Risk of imported cases are managed
6. Communities are fully engaged in the transition



Source: WHO. (Draft) Transitioning to and maintaining a steady state of low-level or no transmission (15 April 2020)

Shifts in non-pharmacological interventions carry different levels of risk -

Bidirectional shifts may be required during the transition process



Consider:

Healthcare (especially ICU capacity) & public health capacity (test, trace)

Epidemiological indicators (Reproductive Factor should be $R < 1$ to reduce rate of new infections)

Population behaviour will in turn influence value of R

Data and digital solutions to support real-time monitoring and contain the ongoing COVID19 pandemic

Digital solutions

To contact, trace, and limit the propagation


To empower citizens

To facilitate the organisation of the healthcare system capacity

Considerations on use of digital solutions



Example: Google Community Mobility Reports



Sources: European Commission. COMMISSION RECOMMENDATION of 8.4.2020 on a common Union toolbox for the use of technology and data to combat and exit from the COVID-19 crisis, in particular concerning mobile applications and the use of anonymised mobility data

Dual Focus for Health Services Delivery

Balancing COVID care with Health services Recovery

Dual dashboard of key service, coverage, and outcome indicators

COVID-19

Create **public health and laboratory surge capacity** by joining forces with primary care

Improved patient safety and guidelines for care in preparedness for further potential outbreaks

Estimate **surge demand** under new scenarios and procure supplies

Create a **step-wise elastic and flexible plan** for acute and intensive care use

Build on and resource **primary health care** to respond to pent-up and new demand

Enhance and resource **optimized platforms of service delivery** (video, phone, internet)

Strengthen **coordination** between PHC, hospitals, and nursing homes

Identify and remove barriers to seeking care

Health services Recovery

Rethink patient flows for infection prevention and control at system and at facility level

Leave no one behind – prioritize vulnerable populations and create safe spaces

Support health work force

Physical, mental, social exhaustion
of health workforce to cope with
increasing demand over long-
period of time

Revisit your health workforce plans
Ensure protection, rotation, rest, recuperation,
and support for physical, mental and social issues





Monitoring knowledge, risk per behaviours and trust to inform response

SURVEY TOOL AND GUIDANCE

Rapid, simple, flexible behavioural
insights on COVID-19



REGIONAL OFFICE FOR

Behaviour determines virus transmission patterns: Social and behavioural perspectives

Use population tracking/surveys and existing evidence and experience to:

Anticipate	unwanted scenarios and public reactions
Prepare	for these, simulate scenarios in different population segments
Develop	mitigating measures, build trust, and communicate to avoid adverse reactions (risk and crisis communication)



Immunodiagnostic tests

Use of these **new point-of-care immunodiagnostic tests** only recommended **in research settings**.

WHO continues to evaluate available immunodiagnostic tests for COVID-19 - Quality is essential to be able to rely on these in transition

Vaccines and therapeutics

Two candidate vaccines are currently in clinical evaluation phase.

Plan for acquisition of vaccines

WHO Solidarity Trial for therapeutics



Going Forward Together

Isolate, test, trace and contain

Flexible two-track health system response

Leverage population insights for engagement

Protect the vulnerable and leave no one behind

Coordinate, mobilize, and build confidence

Work together in solidarity

Recover better - Use COVID-19 for learning

Thank you

WHO Regional Office for Europe

UN City
Marmorvej 51
Copenhagen Ø
Denmark



WHO_Europe



facebook.com/WHOEurope



instagram.com/whoeurope



youtube.com/user/whoeuro



REGIONAL OFFICE FOR

World Health
Organization

Europe



BUREAU RÉGIONAL DE L'

Organisation
mondiale de la Santé

Europe



REGIONALBÜRO FÜR

Weltgesundheitsorganisation

Europa



Всемирная организация
здравоохранения

Европейское региональное бюро